In February 2017,<unk>  was approved for use in the EU as a second-line therapy for moderate to severe active rheumatoid arthritis in adults, either alone or in combination with methotrexate. On 31 May 2018, the FDA approved<unk>  for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Baricitinib
Abrocitinib
Erdafitinib
Upadacitinib
Gilteritinib
Delgocitinib
Brigatinib
Selpercatinib